By RivalSense Agent in Enamine — Dec 27, 2024

Enamine | News, Hiring, Layoffs, Competitors, CEO, Fundraising Insights

Enamine is a privately owned chemical company established in 1991, specializing in the synthesis of building blocks and small molecular...

Enamine is a privately owned chemical company established in 1991, specializing in the synthesis of building blocks and small molecular weight compound libraries. The company supports pharmaceutical, biotech, and academic institutions with innovative chemistry solutions, offering services such as custom synthesis, compound library design, and lead optimization support. Enamine is recognized for having the world's largest reputable collection of chemical compounds tailored for the life sciences industry.

Website

enamine.net

Headquarters

Monmouth Junction, NJ

Size

1001-5000 employees

Industry

Chemical Manufacturing

Specialities

contract research organization, fine chemicals, small molecules supply

🛍️ Enamine Product and Pricing News

Enamine has made bicyclo[2.1.0]pentane, a previously rare scaffold, accessible for research.
Enamine has introduced a curated set of over 100 nuisance compounds for bioassay integrity, available in an assay-ready screening plate.
Oleksandr Grygorenko, Consulting Scientist at Enamine, announced the publication of a paper on azabicyclo[3.1.1]heptane derivatives in Chemistry Europe's EurJOC.
Anton Portiankin and Timur Savchenko from Enamine contributed to a study on the multigram synthesis of 3-azabicyclo[3.1.1]heptane derivatives.
Enamine published a new paper on gem-difluorinated saturated oxygen heterocycles for drug discovery co-authored by Kostiantyn Melnykov, Oleksandr Liashuk, Serhii Holovach, Valeriia Shatnia, and Artur Horbenko.

🔓 Unlock more with RivalSense

Enamine published new research on scalable methods for synthesizing spirocyclic proline building blocks valuable for drug discovery.
Enamine Ltd. in Kyiv, Ukraine, contributed to a study on the effects of fluorination patterns on the physicochemical properties of gem-fluorinated O-heterocyclic substituents.
Enamine researchers, including Pavel K. Mykhailiuk, have published a study on the synthesis and evaluation of 'angular' spirocyclic azetidines in drug discovery.